Clinical Trial Detail

NCT ID NCT01888562
Title Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Recruitment Withdrawn
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

endometrial carcinoma

Therapies

Ponatinib

Age Groups: adult

Additional content available in CKB BOOST